BA vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Boeing Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-07.
The Boeing Company · Industrials
$234.54
+45.0% upside to fair value
Grade C
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
BA has more upside to fair value
(+45.0%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
BA |
PFE |
| Current Price |
$234.54 |
$25.22 |
| Fair Value Estimate |
$340.08 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$184.9B |
$143.7B |
| Forward P/E |
96.9x
|
19.2x
|
| EV / EBITDA |
30.4x
|
12.3x
|
| Price / Sales |
2.0x
|
2.3x
|
| Price / FCF |
-177.6x
|
15.2x
|
| Revenue Growth YoY |
+14.0%
|
+5.4%
|
| Gross Margin |
4.8%
|
69.3%
|
| Operating Margin |
-5.9%
|
23.4%
|
| Return on Equity |
-8723.1%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
—
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
The Boeing Company operates in the Industrials sector within the Aerospace & Defense industry, manufacturing commercial jetliners, defense, space, and security systems. Despite a challenging operating margin of -5.9% and a negative free cash flow per share of -2.46, Boeing shows strong recent earnings growth of 89.2% and revenue growth of 14.0% in the most recent quarter, signaling a potential re…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
BA |
PFE |
| Zone Low |
$255.06 |
$19.44 |
| Zone High |
$289.07 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|